ANI Pharmaceuticals buys four AstraZeneca NDAs

This article was originally published here

ANI Pharmaceuticals has acquired the new drug applications (NDAs) and US marketing rights for AstraZeneca’s Atacand, Atacand HCT, Arimidex, and Casodex for $46.5m.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply